Journal
DERMATOLOGIC CLINICS
Volume 37, Issue 2, Pages 205-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.det.2018.12.007
Keywords
Atopic dermatitis; Crisaborole; Dupiluamb; Tralokinumab; Lebrikizumab; Fezakinumab; GBR 830; JAK inhibitors
Categories
Ask authors/readers for more resources
The evolving discoveries in atopic dermatitis (AD) shed light on disease pathogenesis and allow better management of patients. Dupiluamab was the first targeted agent approved for AD, proving for the first time AD can be treated with a single cytokine antagonism. Nevertheless, because not all patients respond to dupilumab and AD has a heterogeneous phenotype, more treatment options are much needed. This article reviews recent and exciting developments in AD, because ongoing or pipeline clinical trials for AD will ultimately expand and redefine a novel treatment paradigm for this common disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available